{"prompt": "['Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients', 'with inhibitor after failing immune tolerance induction: A prospective clinical case series.', 'Haemophilia 2010;16:90-100.', 'Ewenstein BM, Valentino LA, Journeycake JM, et al. Consensus recommendations for use', 'of central venous access devices in haemophilia. Haemophilia 2004;10:629-48.', 'Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013;27:179-84.', 'Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in', 'haemophilia A therapy - global progress towards optimal care. Haemophilia 2006; 12:75-81.', 'Gringeri A, Lundin B, Von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical', 'trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost', '2011;9:700-10.', 'Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study:', 'a randomized dose comparison. Blood 2012;119:1335-44.', 'Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-', 'level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-36.', 'Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L', 'compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res', '2013;22:1717-27.', 'Karaman K, Akbayram S, Garipardi\u00e7 M, \u00d6ner AF. Diagnostic evaluation of our patients with', 'hemophilia A: 17-year experience. Turk Arch Pediatr 2015;50:96-101.', 'Kempton CL, White Il GC. How we treat a hemophilia A patient with a factor VIII inhibitor.', 'Blood 2009;113:11-7.', 'Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients', 'with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J', 'Haematol 2012;88:329-35.', 'Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of', 'recombinant factor Vlla for secondary prophylaxis in hemophilia patients with inhibitors. J', 'Thromb Haemost 2007;5:1904-13.', 'Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in', 'hemophilia with inhibitors. N Engl J Med 2011;365:1684-92.', 'Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated', 'prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in', 'paediatric patients with haemophilia A and inhibitors. Haemophilia 2007;13:249-55.', 'Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial', '(guardianT1) using prophylactic treatment with turoctocog alfa in adolescent and adult', 'patients with severe haemophilia A: safety and efficacy. Haemophilia 2013;19:691-7.', 'Lundkvist M, Engdahl E, Holm\u00e9n C, et al. Characterization of anti-natalizumab antibodies in', 'multiple sclerosis patients. Mult Scler J 2012;19:757-64.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '155 / Protocol MO39129, Version 3']['Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion', 'protein in severe hemophilia A. Blood 2014;123:317-25.', 'Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to', 'prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44.', 'Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group', 'trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant', 'factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013;11:1119-', '27.', 'Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review.', 'Semin Thromb Hemost 2003;29:069-76.', 'NIH. National Institutes of Health: National Heart, Lung, and Blood Institute. What Is', 'Hemophilia? Available from: http://www.nhlbi.nih.gov/health/health-topics/topics/hemophilia.', 'Last accessed: 17 August 2016', 'Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with', 'inhibitors. NEJM 2017;277(9):809-18.', 'Plug I, Mauser-Bunschoten EP, Br\u00f6cker-Vriends AHJT, et al. Bleeding in carriers of', 'hemophilia. Blood 2006;108:52-6.', 'Pollak E, M\u00fchlan H, Von Mackensen S, Bullinger M. The Haemo-Qol Index: developing a', 'short measure for health-related quality of life assessment in children and adolescents with', 'haemophilia. Haemophilia 2006;12:384-92.', 'Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion', 'protein in hemophilia B. N Engl J Med 2013;369:2313-23.', 'Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an', 'asymmetric bispecific igg antibody mimicking the function of factor viii cofactor activity.', 'PLOS ONE 2013;8:e57479.', 'Sampson HA, Mu\u00f1oz-Furlong A, Campbell RL, et al. Second symposium on the definition', 'and management of anaphylaxis: Summary report-Second National Institute of Allergy and', 'Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin', 'Immunol 2006;117:391-7.', 'Santagostino E, Morfini M, Auerswald GK-H, et al. Paediatric haemophilia with inhibitors:', 'existing management options, treatment gaps and unmet needs. Haemophilia 2009;15:983-', '9.', 'Santagostino E, Lentz SR, Busk AK, Regnault A, lorio A. Assessment of the impact of', 'treatment on quality of life of patients with haemophilia A at different ages: insights from two', 'clinical trials on turoctocog alfa. Haemophilia 2014;20:527-34.', 'Schrijvers LH, Uitslager N, Schuurmans MJ, Fischer K. Barriers and motivators of adherence', 'to prophylactic treatment in haemophilia: a systematic review. Haemophilia 013;19:355-61.', 'Shankar G, Arkin S, Cocea L, et al. Assessment and reporting of the clinical immunogenicity', 'of', 'therapeutic proteins and peptides-harmonized terminology and tactical', 'recommendations. AAPS J 2014;16:658-73.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '156 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}